Candriam S.C.A. Vir Biotechnology, Inc. Transaction History

Candriam S.C.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$9.14 - $24.62 $3.14 Million - $8.46 Million	-343,619 Reduced 96.89%	11,026 $103,000
Q2 2023 Aug 08, 2023	BUY	$23.2 - $27.29 $8.23 Million - $9.68 Million	354,645 New	354,645 $8.7 Million
Q2 2021 Jul 20, 2021	SELL	$38.75 - $51.0 $8.77 Million - $11.5 Million	-226,238 Closed	0 $0
Q4 2020 Jan 22, 2021	BUY	$25.51 - $43.38 $525,914 - $894,322	20,616 Added 10.03%	226,238 $6.06 Million
Q3 2020 Oct 19, 2020	BUY	$28.28 - $53.6 $5.81 Million - $11 Million	205,622 New	205,622 $7.06 Million

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.